newsfilter
← Latest News
GlobeNewswire·

Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update

- Topline data for pivotal abuse study of the Company's lead investigational program ADAIR expected this quarter - Second development program, ADMIR, continues to advance with first-in-humanclinical trial expected to commence in 2022 PHILADELPH